Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 27, 2018 | June 29, 2018 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 12, 2018 | June 14, 2018 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | October 02, 2026 | October 06, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director · Chief Executive Officer | February 17, 2026 | February 19, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, COO | June 29, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date June 27, 2018 · Filed June 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.15 · Expires 2028-06-27 | Direct | 15,000 |
Reported balance
After 2018-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-27 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
INFINITY PHARMACEUTICALS, INC.
Report date June 12, 2018 · Filed June 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,845 |
Reported balance
After 2018-06-12 transaction · row 1
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 22,857 · Balance 45,845 F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 20,000 |
Reported balance
After 2018-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000 F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 4,000 |
Reported balance
After 2018-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-12 · Grant · Acquired 4,000 · Balance 4,000 F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.
F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Solid Biosciences Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,585 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Exercise / conversion · Acquired 3,440 · Balance 141,585 F1: Restricted stock units convert to common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,440 |
Reported balance
After 2026-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-02 · Exercise / conversion · Disposed 3,440 · Balance 3,440 F1: Restricted stock units convert to common stock on a one-for-one basis. F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert to common stock on a one-for-one basis.
F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.
Stoke Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.09 · Expires 2036-02-16 | Direct | 193,000 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 193,000 · Balance 193,000 F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-02-15 | Direct | 129,000 |
Reported balance
After 2026-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-17 · Grant · Acquired 129,000 · Balance 129,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.
F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,699 |
Ending reported balance
After 2018-06-29 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-06-29 · Exercise / conversion · Acquired 23,375 · Balance 70,074 Row 2 · 2018-06-29 · Sale · Disposed 4,741 · Balance 65,333 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89). F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2018-06-29 · Sale · Disposed 18,634 · Balance 46,699 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.89 · Expires 2025-07-20 | Direct | 10,625 |
Reported balance
After 2018-06-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-29 · Exercise / conversion · Disposed 23,375 · Balance 10,625 F5: The option vests in 16 quarterly installments from 7/21/2015. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,306 |
Reported balance
Holding disclosure · report date 2018-06-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,306 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).
F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).
F5: The option vests in 16 quarterly installments from 7/21/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2018 Filed May 4, 2018 17:50 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,677 | $23.46 | $86,277.50 |
DisclosureSEC source: 0001209191-18-028179 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,323 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $22.7750 to $23.7000 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 02, 2018 Filed May 4, 2018 17:50 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 10,000 | $20.16 | $201,600.00 |
DisclosureSEC source: 0001209191-18-028179 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy · Derivative | 51,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · derivative · entry 15 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 51,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy · Derivative | 2,125 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · derivative · entry 14 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125 Underlying: Common Stock · 2,125 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 53,125 | $160.12 | $8,506,375.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 9 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $160.12 (range $160.00 to $160.23). Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 51,000 | $109.14 | $5,566,140.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 8 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $96.87 | $205,848.75 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy · Derivative | 7,766 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · derivative · entry 13 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,299 Underlying: Common Stock · 7,766 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy · Derivative | 2,156 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · derivative · entry 12 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,241 Underlying: Common Stock · 2,156 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy · Derivative | 4,250 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · derivative · entry 11 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,250 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $156.78 | $423,306.00 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $156.78 (range $156.38 to $157.29). Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,790 | $155.62 | $1,523,519.80 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,399 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $155.62 (range $155.32 to $156.29). Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19,478 | $154.98 | $3,018,700.44 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,189 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $154.98 (range $154.32 to $155.31). Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,766 | $86.52 | $671,914.32 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,156 | $91.05 | $196,303.80 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,250 | $77.31 | $328,567.50 |
DisclosureSEC source: 0001209191-18-026607 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 19,566 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-18-008556 · doc4.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,566 Underlying: Common Stock · 19,566 shares Expires 2028-02-05 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008556 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,495 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 15,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008556 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,058 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/03/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-003963 · doc4.xml · derivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 2,125 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/15/2014. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $159.29 | $79,645.00 |
DisclosureSEC source: 0001209191-18-003963 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $159.29 (range $158.96 to $159.65). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $158.11 | $63,244.00 |
DisclosureSEC source: 0001209191-18-003963 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,388 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $158.11 (range $157.77 to $158.67). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $157.02 | $62,808.00 |
DisclosureSEC source: 0001209191-18-003963 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,788 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $157.02 (range $156.62 to $157.50). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 825 | $155.80 | $128,535.00 |
DisclosureSEC source: 0001209191-18-003963 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,188 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $155.80 (range $155.32 to $156.26). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $96.87 | $205,848.75 |
DisclosureSEC source: 0001209191-18-003963 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7 | $147.29 | $1,031.03 |
DisclosureSEC source: 0001209191-17-061525 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 22:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-17-059638 · doc4.xml · derivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/5/2014. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 22:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,250 | $150.00 | $637,500.00 |
DisclosureSEC source: 0001209191-17-059638 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 22:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,250 | $77.31 | $328,567.50 |
DisclosureSEC source: 0001209191-17-059638 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 22:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-17-059638 · doc4.xml · derivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,397 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 22:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,155 | $150.00 | $323,250.00 |
DisclosureSEC source: 0001209191-17-059638 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 22:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-17-059638 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $149.34 | $29,868.00 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 8 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,791 | $148.26 | $562,053.66 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,088 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $148.26 (range $147.93 to $148.70). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,500 | $147.40 | $515,900.00 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,879 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $147.40 (range $146.93 to $147.90). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,200 | $146.39 | $761,228.00 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,379 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $146.39 (range $145.30 to $146.92). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 22,464 | $145.26 | $3,263,120.64 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,579 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.93 to $145.87). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 32,945 | $144.47 | $4,759,564.15 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,043 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $144.47 (range $143.91 to $144.89). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,200 | $143.47 | $746,044.00 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,988 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $143.47 (range $142.91 to $143.85). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $142.40 | $242,080.00 |
DisclosureSEC source: 0001209191-17-058481 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,188 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $142.40 (range $141.83 to $142.75). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-17-057320 · doc4.xml · derivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Common Stock · 2,125 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/15/2014. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $157.07 | $31,414.00 |
DisclosureSEC source: 0001209191-17-057320 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $157.07 (range $156.96 to $157.17). Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 850 | $156.24 | $132,804.00 |
DisclosureSEC source: 0001209191-17-057320 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,088 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $156.24 (range $155.86 to $156.73). Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 875 | $155.03 | $135,651.25 |
DisclosureSEC source: 0001209191-17-057320 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,938 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $155.03 (range $154.75 to $155.52). Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $154.01 | $30,802.00 |
DisclosureSEC source: 0001209191-17-057320 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,813 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $154.01 (range $153.58 to 154.43). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $96.87 | $205,848.75 |
DisclosureSEC source: 0001209191-17-057320 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-17-048255 · doc4.xml · derivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 4,250 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/5/2014. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,250 | $156.02 | $195,025.00 |
DisclosureSEC source: 0001209191-17-048255 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,888 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $156.02 (range $155.87 to $156.26). Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,600 | $155.29 | $403,754.00 |
DisclosureSEC source: 0001209191-17-048255 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,138 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $155.29 (range $154.82 to $155.80). Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $154.09 | $61,636.00 |
DisclosureSEC source: 0001209191-17-048255 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,738 F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $154.09 (range $153.67 to $154.50). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.